Company

Kailera Therapeutics

Biotechnology Research Weight Bias - the First Step in Challenging IT and Advocating for More Inclusive and Equitable Environments. 121 employees

Employees: 121
Contacts: 4
Emails: 4
Phones: 2

LinkedIn Crunchbase

Kailera Therapeutics Overview

Headquarters: Weight Bias - the First Step in Challenging IT and Advocating for More Inclusive and Equitable Environments.
Industry: Biotechnology Research
Employees: 121
Founded: 2024
Funding: 400.0M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

About Kailera Therapeutics

Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive clinical trial results in obesity in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com.

Kailera Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 4
Email contacts: 4; 100.0% coverage
Phone contacts: 2; 50.0% coverage

Kailera Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Paul Burgess	COO and Cbo Kailera Therapeutics	Wellesley Hills, Massachusetts, United States	Email
Laurie Stelzer		United States	Email Phone
Richard Gleeson		Warrington, Pennsylvania, United States	Email
Ron Renaud	President & CEO - Kailera Therapeutics	Waltham, Massachusetts, United States	Email Phone